StemCell Institute () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Cyfuse Biomedical KK

Peptidream, Inc.

SUSMED, Inc.

Chiome Bioscience, Inc.

StemCell Institute

OncoTherapy Science, Inc.

GNI Group Ltd.

Oncolys BioPharma, Inc.

Carna Biosciences, Inc.

MEDINET Co., Ltd.

Stella Pharma Corp.

Why is StemCell Institute ?

Negative results in Dec 25

INTEREST(9M) At JPY 3.94 MM has Grown at inf%
NET PROFIT(HY) At JPY 101.41 MM has Grown at -37.24%
ROCE(HY) Lowest at 7.13%

With ROE of 14.68%, it has a very attractive valuation with a 4.04 Price to Book Value

The stock is trading at a premium compared to its peers' average historical valuations
Over the past year, while the stock has generated a return of -39.47%, its profits have risen by 24.5% ; the PEG ratio of the company is 1.1

Consistent Underperformance against the benchmark over the last 3 years

Along with generating -39.47% returns in the last 1 year, the stock has also underperformed Japan Nikkei 225 in each of the last 3 annual periods

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is StemCell Institute for you?

Low Risk, Low Return

Absolute

Risk Adjusted

Volatility

StemCell Institute

-100.0%

-1.40

36.44%

Japan Nikkei 225

38.94%

1.30

28.24%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

14.56%

EBIT Growth (5y)

22.63%

EBIT to Interest (avg)

100.00

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-1.03

Sales to Capital Employed (avg)

0.91

Tax Ratio

31.80%

Dividend Payout Ratio

66.37%

Pledged Shares

Institutional Holding

ROCE (avg)

ROE (avg)

10.52%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

4.04

EV to EBIT

18.92

EV to EBITDA

14.48

EV to Capital Employed

-116.15

EV to Sales

2.96

PEG Ratio

1.12

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

14.68%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bullish

Bearish

Moving Averages

Bearish (Daily)

KST

Bullish

Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

2What is working for the Company

RAW MATERIAL COST(Y)

Fallen by 1.15% (YoY

NET SALES(Q)

Highest at JPY 728.92 MM

-15What is not working for the Company

INTEREST(9M)

At JPY 3.94 MM has Grown at inf%

NET PROFIT(HY)

At JPY 101.41 MM has Grown at -37.24%

ROCE(HY)

Lowest at 7.13%

DEBTORS TURNOVER RATIO(HY)

Lowest at 1.36 times

INVENTORY TURNOVER RATIO(HY)

Lowest at 19.69 times

Here's what is working for StemCell Institute

Net Sales

Highest at JPY 728.92 MM

in the last five periods

MOJO Watch

Near term sales trend is positive

Net Sales (JPY MM)

Raw Material Cost

Fallen by 1.15% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation

Highest at JPY 39.35 MM

in the last five periods

MOJO Watch

The expenditure on assets done by the company may have gone into operation

Depreciation (JPY MM)

Here's what is not working for StemCell Institute

Interest

At JPY 3.94 MM has Grown at inf%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (JPY MM)

Net Profit

At JPY 101.41 MM has Grown at -37.24%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is negative

Net Profit (JPY MM)

Debtors Turnover Ratio

Lowest at 1.36 times and Fallen

In each half year in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Inventory Turnover Ratio

Lowest at 19.69 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio